Stock Events

Hikma Pharmaceuticals 

€22.2
202
+€0+0% Today

Statistics

Day High
22.2
Day Low
22.2
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
4.93B
P/E Ratio
27.95
Dividend Yield
3.04%
Dividend
0.68

Upcoming

Dividends

3.04%Dividend Yield
10Y Growth
15.62%
5Y Growth
12.64%
3Y Growth
14.75%
1Y Growth
15.42%

Earnings

8AugConfirmed
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Next
0
25.27
50.55
75.82
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H5P.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, directly competing with Hikma in the generics and branded drugs markets.
Novartis
NVS
Mkt Cap232.42B
Novartis is a large multinational pharmaceutical company with a strong presence in generic drugs through its Sandoz division, making it a direct competitor to Hikma.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical corporation with a broad portfolio that includes generic drugs, competing with Hikma in various therapeutic areas.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie, known for its significant research-based pharmaceuticals, competes with Hikma in the specialty pharmaceuticals market, particularly in areas like immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Hikma in the development and marketing of pharmaceuticals for various therapeutic areas.
Merck &
MRK
Mkt Cap318.55B
Merck & Co. is a global healthcare company that competes with Hikma in the development, manufacturing, and marketing of pharmaceuticals and vaccines.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline is a global healthcare company that competes with Hikma in the pharmaceutical and vaccines sectors, with a broad portfolio of products.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is a global pharmaceutical company that competes with Hikma in the areas of generics, specialty care, and vaccines.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Hikma in the development and commercialization of prescription medicines across multiple therapy areas.

About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Show more...
CEO
Engineer Said Samih Taleb Darwazah
Employees
9100
Country
GB
ISIN
GB00B0LCW083
WKN
000A0HG69

Listings